Tagged with R

Boehringer Ingelheim Romania If we take a look back at Boehringer Ingelheim’s dynamic growth path in the Romanian market, we see an evolution from a one-man show in the 1990s to a present day subsidiary of over 100 people. What have been the key milestones and achievements for you since joining this subsidiary…

CMS Russia How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the last five years, we have been truly active in the Russian life sciences market. In general, CMS has adopted a…

Servier Russia With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted this drive, and has had a Russian facility since 2007, the same year you took this position. Russia has traditionally…

Euroservice You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of 6 people to the ninth-ranking importing distributor in this country? I believe that it is of some value, especially in…

Protek In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly after the world financial crisis, which hit Russia particularly hard. Why did you choose this very risky period for the…

Scottish Enterprise What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish government has set out an economic strategy in which they identify six key industrial sectors for the growth of the…

PAREXEL Russia PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better than its competitors? For pharma companies, time is always money—the tendency and drive, therefore, is to get products to market…

NAARI AG Russia/CIS Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you believe the game has changed for foreign companies looking to play in Russia? Firstly, it is necessary to specify the…

Biocodex Russia You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history of working in the luxury goods industry, but no pharmaceutical management experience. How do you navigate the challenge of entering…

Merz Russia You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may view this as a step down. What attracted you to this organization? First of all, the position itself was very…

Lupin Russia Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to drug registration and establishing the mutual recognition of clinical trials. On a socio-economic level, wow would you describe the synergies…

BOIRON Romania Records show that the field of homeopathy has a long history in Romania, dating back to the late 1800s. However, the real growth only really took off in the 1990s. Can you give a brief introduction on homeopathy in Romania and what have been some of the key milestones for…